Top Markets
#1 Resolv wstUSR Resolv wstUSR +114.62%
#2 Luxxcoin Luxxcoin +45.27%
#3 ResearchCoin ResearchCoin +22.78%
#4 Reactive Network Reactive Network +20.67%
#5 Orderly Network Orderly Network +16.77%
#6 Layer3 Layer3 +13.71%
#7 Bitgert Bitgert +13.08%
#8 Aria.AI Aria.AI +11.86%
#9 Useless Coin Useless Coin +9.66%
#10 Lisk Bridged wstETH (Lisk) Lisk Bridged wstETH (Lisk) +9.53%
Coin of the day
Resolv wstUSR Resolv wstUSR
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
CSL Limited CSL Limited

CSL Limited

CSL
Classifica tra le azioni #432
CSL Limited researches, develops, manufactures, markets, and distributes... CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and CSL Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The CSL Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.
Prezzo delle azioni
$99.32
Capitalizzazione di mercato
$48.20B
Variazione (1 giorno)
0.98%
Variazione (1 anno)
-32.14%
Paese
AU
Scambia CSL Limited (CSL)

Categoria

Healthcare
Ricavi di CSL Limited (CSL)
Ricavi nel Dec 2025 TTM: $15.70B
Secondo gli ultimi rapporti finanziari di CSL Limited, i ricavi attuali dell'azienda (TTM) sono pari a $15.70B. Nel 2024, l'azienda ha registrato ricavi di $14.69B un aumento rispetto a i ricavi dell'anno 2023, che erano pari a $13.17B. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per CSL Limited da 2000 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
2026 (TTM) $15.70B 1.72%
2025 $15.43B 5.04%
2024 $14.69B 11.51%
2023 $13.17B 25.55%
2022 $10.49B 1.56%
2021 $10.33B 9.84%
2020 $9.41B 13.08%
2019 $8.32B 11.54%
2018 $7.46B 6.28%
2017 $7.02B 15.81%
2016 $6.06B 11.00%
2015 $5.46B 8.91%
2014 $5.01B 10.79%
2013 $4.52B -2.44%
2012 $4.64B -3.37%
2011 $4.80B 49.63%
2010 $3.21B 6.25%
2009 $3.02B -7.53%
2008 $3.26B 42.87%
2007 $2.28B 45.52%
2006 $1.57B -1.58%
2005 $1.60B 98.59%
2004 $803.28M 36.45%
2003 $588.71M 38.88%
2002 $423.90M -2.21%
2001 $433.49M 0.00%
2000 0.00 0.00%
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 $48.55B 209.32%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.04B -23.30%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 $14.34B -8.62%
US
UCB SA UCB SA
UCB SA
UCB.BR
 $9.08B -42.13%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $5.49B -65.01%
NL